Considering the crucial role of nesfatin-1 in energy and glucose metabolism, we speculated that it might act as a regulatory factor of thyroid function by adjusting AMPK activity and TRH secretion in T2DM patients, thereby resulting in the subclinical hypothyroidism. This evidence concerns the gene TRH and hypothyroidism.